RNS Number : 5833K
MaxCyte, Inc.
02 September 2021
MaxCyte to Report Second Quarter 2021 Financial Results on September 13, 2021
GAITHERSBURG, MD, September 02, 2021 - MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading provider of enabling platform technologies for ex vivo cell engineering, today announced that it will release financial results for the second quarter of 2021 after the U.S. market close on Monday, September 13th, 2021. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.
Conference Call Details
Interested parties may access the live teleconference by dialing (844) 679-0933 for domestic callers or (918) 922-6914 for international callers, followed by Conference ID: 3199124. A live and archived webcast of the event will be available on the "Events" section of the MaxCyte website at https://investors.maxcyte.com/.
About MaxCyte
MaxCyte is a leading provider of cell-engineering platform technologies to advance innovative cell-based research, development and potential commercialization of next-generation cell therapies. The Company's existing customer base ranges from large biopharmaceutical companies - including 20 of the top 25 pharmaceutical companies based on 2020 global revenue - to hundreds of biotechnology companies and academic translational centers. MaxCyte has granted 14 strategic platform licenses to commercial cell therapy developers that allow for more than 75 clinical programs. Founded in 1998, MaxCyte is headquartered in Gaithersburg, Maryland, US.
MaxCyte Contacts:
MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Amanda Murphy, Chief Financial Officer
|
+1 301-944-1660
|
Nominated Adviser and Joint Corporate Broker
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden
|
+44 (0)20 7886 2500
|
Joint Corporate Broker
Numis Securities Limited
James Black / Duncan Monteith / Matthew O'Dowd
|
+44 (0)20 7260 1000
|
Joint Corporate Broker
Stifel Nicolaus Europe Limited
Healthcare Investment Banking
Nicholas Moore / Ben Maddison / Samira Essebiyea
Corporate Broking
Nick Adams
|
+44 (0) 20 7710 7600
|
UK IR Adviser
Consilium Strategic Communications
Mary-Jane Elliott
Chris Welsh
|
+44 (0)203 709 5700
maxcyte@consilium-comms.com
|
US IR Adviser
Gilmartin Group
David Deuchler, CFA
|
+1 415-937-5400
ir@maxcyte.com
|
US Media Relations
Jamie Lacey-Moreira
PressComm PR, LLC
|
+1 410 299-3310
jamielacey@presscommpr.com
|
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the
United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the
London Stock Exchange use the personal data you provide us, please see our
Privacy Policy.
END
NORLTMJTMTTMBJB